Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis

Table 6 Cost-effectiveness of screening strategies when cost estimates are varied in the sensitivity analysis.

Cost Variable	Incremental cost per Active TB case prevented (British Pounds; £'s)
	TST	T-SPOT. TB	QFT-GIT	TST/T-SPOT. TB	TST/QFT-GIT
Basecase Estimates	£47,840^5#	£39,712³	£42,051⁴	£37,206¹	£37,699²
TST cost
£8.07	£45,249⁵	£39,712³	£42,051⁴	£34,478¹	£34,788²
£32.28	£53,024⁵	£39,712¹	£42,051²	£42,662³	£43,523⁴
T-SPOT. TB cost
£45.00	£47,840⁵	£37,008²	£42,051⁴	£35,949¹	£37,699³
£100.00	£47,840⁴	£51,883⁵	£42,051²	£42,862³	£37,699¹
QFT-GIT cost
£35.00	£47,840⁵	£39,712⁴	£39,166³	£37,206²	£36,358¹
£80.00	£47,840⁴	£39,712²	£52,147⁵	£37,206¹	£42,395³
Cost LTBI treatment
£262.30	£22,793³	£23,542⁴	£23,775⁵	£21,036²	£21,031¹
£1,049.18	£97,937⁵	£72,053³	£78,603⁴	£69,547¹	£71,038²
INH hepatitis
£314.56	£47,750⁵	£39,654³	£41,985⁴	£37,148¹	£37,639²
£1,258.24	£48,021⁵	£39,829³	£42,182⁴	£37,322¹	£37,819²
Post exposure TB
£3,809.84	£51,650⁵	£43,522³	£45,858⁴	£41,016¹	£41,509²
£15,239.34	£40,221⁵	£32,093³	£34,437⁴	£29,586¹	£30,080²

^# The superscripts ^1-5 indicate the cost-effectiveness ranking; ⁽¹⁾ indicates most cost effective strategy while ⁽⁵⁾ indicates the least cost-effective strategy. (LTBI - latent tuberculosis infection, TST - Tuberculin Skin Test, INH - isoniazid, QFT-GIT - Quantiferon-TB Gold-In-Tube)

ISSN: 1471-2466